If you could vote on Brexit now which option would you choose?
   

Merck inks yet another $1B-plus supply deal for COVID pill, this time with Japan


Merck & Co.'s positive data for oral COVID-19 antiviral molnupiravir continue to pay off in a big way. Wednesday, just a day after unveiling a $1 billion sale order to the U.S., the company disclosed another major supply deal. Japan has agreed to pay Merck and partner Ridgeback Therapeutics $1.2 billion for 1.6 million courses of the drug, or $750 per course. The deal is contingent on the antiviral winning an authorization or approval from Japan’s Pharmaceuticals and Medical Devices Agency. The deal comes a day after Merck said the U.S. government agreed to purchase another 1.4 million courses of the drug for $1 billion. Together with an earlier purchase, the order brings the United States' total supply purchase to 3.1 million courses at a cost of $2.2 billion.

FiercePharma - November 11, 2021

View the full story here: https://www.fiercepharma.com/pharma/merck-inks-yet-another-1b-molnupiravir-supply-deal-time-japan